




FIG. 1A




FIG. 1B




FIG. 2




FIG. 3




FIG. 4

5/13

PKMYT1 Expression
Tumor vs Normal




FIG. 5




FIG. 6




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B






FIG. 9




2 biological replicates performed for PPP2R2A/PKMYT1 pair in Huh1 cells. 3 technical replicates per study. One-way Anova statistical approach used to calculate significance between PPP2R2A, PKMYT1, and combination.

FIG. 10



GeneA-PKMYT1 Results in Hep3B cell line. Synergy was measured by calculation of Excess Over Bliss (EOB); Lethality was measured and expressed as Fractional Viability (FV) based on the fraction of cells in culture compared to control cell lines.

FIG. 11

Hep3B (liver)
N=2

Inhibition of PKMYT1 using small molecule inhibitors in isogenic cell lines with PPP2R2A knockout (PPP2R2A-NCC) and control cells line (NCC-NCC). 2 biological replicates performed for each assay, with 3 technical replicates per study. Student's T-test statistical approach used to calculate significance between NCC and PPP2R2A.

FIG. 12